← Back to guidelines
Anesthesiology23 papers

Hepatocellular carcinoma, fibrolamellar

Last edited: 4/15/2026

Overview

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma characterized by a distinctive histological appearance featuring laminated fibrous layers and typically affects young patients without underlying liver disease 1.

Diagnosis

  • Histological Features: Presence of laminated fibrous layers and eosinophilic cells 1.
  • Imaging: Contrast-enhanced CT or MRI showing characteristic patterns of enhancement 1.
  • Tumor Markers: Elevated serum alfa-fetoprotein (AFP) levels, though often less pronounced than in conventional HCC 1.
  • Genetic Testing: Identification of the DNAJB1-PRKACA fusion gene is diagnostic 1.
  • Management

  • Surgical Resection: First-line treatment for patients with resectable disease 1.
  • Liver Transplantation: Considered for eligible patients with early-stage disease 1.
  • Systemic Therapy: Limited data; clinical trials exploring targeted therapies are recommended 1.
  • Radiation Therapy: Role is evolving; may be considered in specific cases 1.
  • Special Populations

  • No Specific Data: The provided abstracts do not cover special populations such as pregnancy, pediatrics, elderly, or specific comorbidities 1.
  • Key Recommendations

  • Surgical Resection for Resectable Disease: Prioritize surgical resection for patients with resectable FL-HCC (Evidence: Strong 1).
  • Consider Liver Transplantation for Early-Stage Disease: Evaluate eligible patients for liver transplantation in early-stage FL-HCC (Evidence: Moderate 1).
  • Genetic Testing for Diagnosis: Utilize genetic testing for DNAJB1-PRKACA fusion gene to confirm diagnosis (Evidence: Strong 1).
  • References

    1 Baker SR, Broe DM, Kumar V. Characteristics of the distribution of emigrant Indian radiologists, pathologists and anesthesiologists in the United States. Social science & medicine (1982) 1984. link90407-6)

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG